- Talis Biomedical Announces Exploration of Strategic Alternatives and Cost Reduction Plan to Preserve Cash
- Talis Biomedical Announces Second Quarter 2023 Financial Results and Business Update
- Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023
- Talis Biomedical Announces Andrew Lukowiak, Ph.D., as President and Chief Scientific Officer (CSO)
- New Data Presented at the Infectious Disease Society for Obstetrics and Gynecology (IDSOG) Annual Meeting Differentiate Talis Biomedical’s Women’s and Sexual Health Product Menu
- Talis Biomedical Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Talis Biomedical Announces 1-for-15 Reverse Stock Split
More ▼
Key statistics
On Friday, Talis Biomedical Corp (TLIS:NAQ) closed at 9.20, -4.17% below its 52-week high of 9.60, set on May 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.18 |
---|---|
High | 9.21 |
Low | 9.18 |
Bid | 9.00 |
Offer | 9.23 |
Previous close | 9.20 |
Average volume | 6.58k |
---|---|
Shares outstanding | 1.82m |
Free float | 1.67m |
P/E (TTM) | -- |
Market cap | 16.76m USD |
EPS (TTM) | -31.44 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼